A Phase 1 Evaluation of the Safety and Tolerability of TAK-228 in Combination With TAK-117 and Paclitaxel in Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Sapanisertib (Primary) ; Serabelisib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 27 Aug 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.
- 29 Nov 2017 Status changed from not yet recruiting to recruiting.
- 18 May 2017 New trial record